Hypothalamic targets for growth hormone secretagogues

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 86, Issue 423, 1997, Pages 88-91

  Robinson, I C A F ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Adrenocorticotrophin; GH secretagogue receptor; Growth hormone secretagogue; Growth hormone releasing hormone; Growth hormone releasing peptide 6; Transgenic rats

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; GROWTH HORMONE RELEASE; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0030726944     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Bowers C, Momany F, Chang D, Hong A, Chang K. Structure-activity relationships of a synthetic pentapeptide that specifically releases GH in vitro Endocrinology 1980; 106:663-7
2. Bowers CY, Momany F, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984;114:1537-45
3. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975-82
4. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993;76:819-23
5. 2 in rats, dogs and monkeys. Life Sci 1990;47:29-36
6. Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab 1992;74:1378-84
7. McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS, et al. Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc Natl Acad Sci USA 1995;92:11165-9
8. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, et al. A nonpeptidyl growth hormone secretagogue. Science 1993;260:1640-3
9. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, et al. Design and biological activities of L-163,191 (MK-0677): a potent active growth hormone secretagogue. Proc Natl Acad Sci USA 1995;92:7001-5
10. Copinschi G, Van Onderbergen A, L'Hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult R, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996;81:2776-82
11. 2 stimulate growth hormone release through distinct receptor sites. J Endocrinol 1991;129:11-19
12. Pong S-S, Chaung L-YP, Dean DC, Nargund RP, Patchett AA, Smith RG. Identification of a new G-protein linked receptor for growth hormone secretagogues. Mol Endocrinol 1996; 10:57-61
13. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection; evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-7
14. Jansson JO, Downs TR, Beamer WG, Frohman LA. Receptor associated resistance to growth hormone-releasing hormone in dwarf 'little' mice. Science 1986;232:511-13
15. Clark RG, Carlsson LMS, Trojnar J, Robinson ICAF. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol 1989;1:249-55
16. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone peptides. In: Bercu BB, Walker RF, editors. Growth hormone II: basic and clinical aspects. New York: Springer-Verlag, 1994:203-22
17. Dickson SL, Leng G, Robinson ICAF. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience 1993;53:303-6
18. Dickson SL, Leng G, Dyball RE, Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology 1995;61:36-43
19. Fairhall KM, Mynett A, Robinson ICAF. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995;144:555-60
20. Guillame V, Magnan E, Cataldi M, Dutour A, Sauze N, Renard M, et al. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994;135:1073-6
21. Fairhall KM, Mynett A, Smith RG, Robinson ICAF. Consistent GH responses to repeated injection of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretaeogue, L-692,585. J Endocrinol 1995;145:417-26
22. Massoud AF, Hindmarsh PC, Matthews DR, Brook CG. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Clin Endocrinol 1996;44:555-62
23. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993;76:1202-8
24. DeBell WK, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. J Clin Endocrinol Metab 1991; 72:1312-16
25. Hickey GJ, Jacks TM, Schleim K-D, Frazier E, Chen HY, Krupa D, et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-1 levels in beagles. J Endocrinol 1997;152:183-92
26. Bercu BB, Yang SW, Masuda R, Hu CS, Walker RF. Effects of coadministered growth hormone (GH)-releasing hormone and GH-releasing hexapeptide on maladaptive aspects of obesity in Zucker rats. Endocrinology 1992;131:2800-4
27. Walker RF, Yang SW, Bercu BB. Robust growth hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci 1991;49:1499-504
28. Flavell DM, Wells T, Wells SE, Carmignac DF, Thomas GB, Robinson ICAF. Dominant dwarfism in transgenic rats by targeting human growth hormone (GH) expression to hypothalamic GH-releasing factor neurons. EMBO J 1996; 15:3871-9
29. Wells T, Flavell DM, Wells SE, Carmignac DF, Robinson ICAF. Effects of growth hormone secretagogues in the transgenic growth-retarded (Tgr) rat. Endocrinology 1997; 138:580-7
30. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D, et al. Effects of acute and repeated intravenous administration of L-692,585, a novel peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, Cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol 1994;143:399-406
31. Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoli SS, Wittreich JM, et al. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab 1994;79:943-9
32. Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995;61:584-9
33. Ciccarelli E, Grottoli S, Razzore P, Gianotti L, Arvat E, Deghenghi R, et al. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acroinegalic but not in hyperprolactinaemic patients. Clin Endocrinol 1996;44:67-71
34. Giustina A, Desenzani P, Perini P, Deghenghi R, Bugari G, Wehrenberg WB, et al. Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog. Endocr Res 1996; 22:159-74
35. Clark RG, Thomas GB, Mortenson DL, Won WB, Ma YH, Tomlinson EE, et al. GH secretagogues stimulate the HPA axis and are diabetogenic in the ZDF rat. Endocrinology 1997;138 (in press)
36. Thomas GB, Fairhall KM, Robinson ICAF. Activation of the hypothalamo-pituitary-adrenal axis by the growth-hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 1997;138:1585-91
37. Hickey GJ, Drisko J, Faidley T, Chang C, Anderson LL, Nicolich S, et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinol 1996;148:371-80
38. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273:974-7
39. Guan X-M, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJS, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol Brain Res 1997 (in press)
40. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989;28:1139-44
41. Dickson SL, Luckman SM. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 1997;138:771-7